Burden of Rotavirus Disease & Impact of Rotavirus Vaccination Umesh D. Parashar, MBBS, MPH Lead, Viral Gastroenteritis Epidemiology Team Centers for Disease.

Slides:



Advertisements
Similar presentations
Module 1 Introduction to rotavirus disease and vaccine
Advertisements

Rotavirus vaccine impact. Introduction. Rotavirus vaccines lead to significant reductions in severe and fatal diarrhea in both vaccinated and unvaccinated.
Rotavirus vaccines Contentious issues and the way forward.
RotaTeq ® Post Marketing Surveillance and Effectiveness Data Dr Swashraya Shah MSD India 24 Dec 2011.
Rotavirus: advocacy slides These slides are intended to support your advocacy efforts. Please incorporate those that may be useful to you in your presentations.
Constructing a cost-effectiveness analysis for a vaccine to prevent rotavirus Roseann Dial RN N287E.
More proven interventions are available to prevent and treat diarrhea than any other major child killer Jones G Bryce J. et al. Lancet UNICEF. Diarrhoea:
Global Burden of Childhood Diarrhea and Pneumonia Christa L. Fischer Walker 1, Igor Rudan 2, Li Liu 1, Harish Nair 2, Evropi Theodoratou 2, Zulfiqar Bhutta.
Rotavirus Vaccine & Health Care Utilization for Diarrhea in U.S Children N Engl J Med 2011;365: Vanessa Craven Clinical Research Fellow.
Foodborne viruses; Rotavirus. 2 Global Impact of Gastroenteritis
Update on Vaccines not Included in this Tender: Rotavirus Vaccines Pre Tender Meeting UNICEF Supply Division, 10-11th December 2008 Ann Ottosen.
Introduction of New vaccines Hib as an Example St. Petersburg Jun 2001.
Hot Topics in Pediatric ID Robert J. Leggiadro, MD Chairman Department of Pediatrics Lincoln Medical Center Professor of Clinical Pediatrics Weill Medical.
U.S. Surveillance Update Anthony Fiore, MD, MPH CAPT, USPHS Influenza Division National Center for Immunizations and Respiratory Disease Centers for Disease.
Bianca L. Tristan, PhD Student Walden University PUBH 8165-Environmental Health Instructor: Dr. Howard Rubin Summer, 2010 Public Health Department Staff.
Monitoring Safety of Rotavirus Vaccines David Martin, MD, MPH CBER Office of Biostatistics and Epidemiology, FDA For presentation at the Vaccines and Related.
Carlos G. Grijalva, MD MPH Department of Preventive Medicine Vanderbilt University School of Medicine Nashville, Tennessee.
Varicella Zoster Virus Herpesvirus (DNA) Primary infection results in varicella (chickenpox) Recurrent infection results in herpes zoster (shingles) Short.
Global Immunization Performance Update through 2011.
Creating an AIDS-Free Generation The beginning of the end of AIDS Center for Strategic & International Studies Washington, DC March 22, 2012 Thomas R.
Protective effect of Natural ROTA virus infection A.J.Chitkara.
DECADES OF VACCINES Vaccine trials: some highs and lows INTERVENTION RESEARCH TO IMPROVE HEALTH IN DEVELOPING COUNTRIES: PROGRESS AND FUTURE CHALLENGES.
1 Universal Immunization Against Rare Diseases  How much is a child’s life worth?  The individual vs society.
WORLD HEPATITIS DAY 2013 Johannesburg, Gauteng 29 th July, 2013 WORLD HEPATITIS DAY 2013 Johannesburg, Gauteng 29 th July, 2013 HEPATITIS B: Post-Vaccination.
Immunization in the Time of H1N1 Anne Schuchat, MD Rear Admiral, US Public Health Service Director, National Center for Immunization and Respiratory Diseases.
Learning from the 2009 H1N1 Pandemic Response 1 Daniel S. Miller MD, MPH Director, International Influenza Unit Office of the Secretary Office of Global.
Rotavirus vaccine coverage among a 2010 birth cohort and risk factors for partial or no coverage, Washington State 2010 K. Stigi, C. DeBolt, K. Lofy Washington.
State Affiliate Challenge 1 South Dakota School Nurses Association Florida Association of School Nurses Delaware School Nurse Association.
U.S. Influenza Surveillance Keiji Fukuda Influenza Branch National Center for Infectious Diseases Centers for Disease Control and Prevention.
Rotavirus Vaccine: use in Wisconsin, effects on primary care visits, hospitalizations, and laboratory detections Jonathan L. Temte, MD/PhD Associate Professor.
US Situation Update and CDC International Response H1N1 Pandemic US Situation Update and CDC International Response Peter Nsubuga, MD, MPH On behalf of.
June 2010 California Pertussis Update. Pertussis Background Pertussis is the most poorly controlled vaccine- preventable disease  Incidence increasing.
1 Using ESSENCE-FL and a serosurvey to estimate total influenza infections, 2009 Richard S. Hopkins, MD, MSPH Kate Goodin, MPH Mackenzie Weise, MPH Aaron.
Introduction for Basic Epidemiological Analysis for Surveillance Data National Center for Immunization & Respiratory Diseases Influenza Division.
Thomas Clark, MD, MPH Centers for Disease Control and Prevention Immunization Program Managers Meeting November 16, 2010 Pertussis Epidemiology in the.
William W. Thompson, PhD Immunization Safety Office Office of the Chief Science Officer Centers for Disease Control and Prevention Impact of Seasonal Influenza.
Rotavirus & Rotavirus Vaccine By Dr. Asad Ramlawi DGPHC & PH Beithlehem / Palestine.
Rotarix: PMS Dr. Shailesh MEHTA GSK IAPCOI meeting Mumbai, 24 th Dec 2011.
N Engl J Med 2010; 362: January 28, 2010 Presenters ; Dr Ngwenya/Dr Nchimba.
Vaccines and Related Biological Products Advisory Committee Meeting July 23, 2009 Novel influenza A (H1N1) Epidemiology Update Anthony Fiore, MD, MPH Influenza.
Hospital Based Surveillance to Estimate the Burden of Rotavirus Gastroenteritis Among European Children Younger than 5 Years of Age Johannes Foster, Alfredo.
Training for rotavirus vaccine introduction Module 1 Introduction to rotavirus disease and vaccine.
Can we achieve rotavirus vaccine immunization worldwide by 202X? Global Vaccines 202X: Access, Equity, Ethics May 3, 2011.
Pertussis and Pertussis Vaccines Epidemiology and Prevention of Vaccine- Preventable Diseases National Center for Immunization and Respiratory Diseases.
Anne Schuchat, MD Director, National Center for Immunization and Respiratory Diseases, CDC Assistant Surgeon General, US Public Health Service CVEP Symposium.
"Epidemiological Features of Rotavirus Infection among children below 5 years old in Jordan, Rationale for Vaccine Introduction,2015" Kareman Juma`ah Al-Zain.
A global partnership to stop measles & rubella 1 Measles & Rubella Initiative --Who We Are-- Stephen Cochi, MD, MPH Global Immunization Division Centers.
Update on Effectiveness and Safety of Rotavirus Vaccines Umesh D. Parashar Lead, Viral Gastroenteritis Team Centers for Disease Control Prevention Atlanta,
Trends in Tetanus Epidemiology in the United States, Pamela Srivastava MS Bacterial Vaccine-Preventable Disease Branch, National Immunization.
Pneumococcal Vaccine Use Around the World: Successes and Challenges Adam L. Cohen, MD MPH Respiratory Diseases Branch, Division of Bacterial Diseases Centers.
CVD Testing the H1N1 Pandemic Flu Vaccines Mini-Med School Karen Kotloff, MD University of Maryland School of Medicine Center for Vaccine Development September.
Using Medical Claims Data for Timely Estimation of Rotavirus Vaccine Coverage Lone Simonsen, George Washington University and SDI Farid Khan and Laurel.
Rotavirus: advocacy slides
Chapter 13 Rotavirus. Learning outcomes Define retrovirus, cause,symptoms Vaccine available and prevention steps for parent.
Accelerating Vaccine Introduction in Low-resource Countries
Impact of Rotavirus Vaccination in Latin America
Etiology of Acute Gastroenteritis in Hospitalized Children?
Immunization Update 2007 Rotavirus Vaccine Segment
From: Rotarix: A Rotavirus Vaccine for the World
Umesh D. Parashar CDC, Atlanta, GA
Progress and Challenges with achieving Universal Immunization Coverage
Global Update on Varicella: Protecting Against an Old Enemy
Jepkoech Kottutt1, Emilia D. Rivadeneira2, Susan Hrapcak2
The State of Pneumococcal Disease Prevention
Ph.D. Public Health Student
National Immunization Conference-April 22, 2010
MenB Update: Communicating the Imperative With Parents
Rotavirus Vaccines An Update
Serotype 10A in Invasive Pneumococcal Disease (IPD) Surveillance in New Jersey, April – September 2009 Samantha Pitts, MD, MPH CDC/CSTE Applied Epidemiology.
School-Based Immunization for Control of Influenza?
Presentation transcript:

Burden of Rotavirus Disease & Impact of Rotavirus Vaccination Umesh D. Parashar, MBBS, MPH Lead, Viral Gastroenteritis Epidemiology Team Centers for Disease Control Prevention Atlanta, GA TM 1

Rotavirus is the Leading Cause Of Severe Gastroenteritis in Children <5 Years 2 Other Bacterial Rotavirus Developed CountriesDeveloping Countries Unknown Rotavirus A. Kapikian, Fields Virology 2003

The face of rotavirus Diarrhea Vomiting Dehydration Shock Death

4 Burden of Rotavirus in the US in Deaths 55-70,000 Hospitalizations 500,000 Outpatient visits 3.2 Million episodes Cost: $300 M medical; >$1 B total CDC, MMWR, 2006

5 1 dot = 250 deaths Global Distribution of 527,000 Annual Rotavirus Deaths in Young Children Parashar et al, JID, 2009

Phase 3 Trials of Two Rotavirus Vaccines 6 Trials of 60-70,000 infants No increased risk of intussusception or other SAE Efficacy of 85%-98% against severe disease Vesikari et al and Ruiz-Palacios et al, NEJM 2006

Countries in the Americas with Rotavirus Vaccine Programs Rotarix only No program Rotateq & Rotarix Rotateq only

8 Rotavirus Vaccines in USA Feb 2006 – RotaTeq recommended June 2008 – Rotarix recommended

National Rotavirus Laboratory Surveillance Network of 67 laboratories reporting since 2000 Weekly reporting: – # specimens tested for rotavirus – # positive tests

* 3-week moving averages Vaccine introduced Total and Positive Rotavirus Tests, July 2000-Mar 2010 Tate et al, Pediatrics 2009 and CDC unpublished data

11 Active Rotavirus Surveillance Payne et al, PAS 2009

12 Total AGE and Rotavirus AGE Hospitalizations NVSN, % Rota + 45 % Rota + 6 % Rota + National reduction of 45,000-62,000 hospitalizations in 2008

13 AgeDecline in rotavirus hospitalization rate (2008 vs. 2006) Rotavirus vaccine coverage in 2008 (>=1 dose) < 1 year66%56% 1 -< 2 years95%44% 2 -< 3 years85%<1% This age cohort was ineligible to receive rotavirus vaccine Age-Specific Rotavirus Hospitalization Rate Reduction and Vaccine Coverage, NVSN

14 Rotavirus Vaccination in El Salvador October 2006 – Rotarix recommended

15 Reduction in Rotavirus Admissions in Children < 5 Years after Rotarix Introduction, El Salvador 70-80% reduction in rotavirus hospitalizations children < 5 years In press, BMJ, 2010

16 Richardson et al, NEJM 2010

17 Marked Decline in Childhood Diarrhea Deaths After Rotarix Introduction, Mexico Vaccine Introduction (May 2007)

18 Winter Blunting of Diarrhea Deaths Suggests Effect Against Rotavirus

19 1 dot = 250 deaths Global Distribution of 527,000 Annual Rotavirus Deaths in Young Children

20 Rotarix Trial in Malawi & So. Africa Region Vaccine Efficacy 95% CI No. of rotavirus cases prevented per 100 vaccinated Malawi 49%19, South Africa77%40, Madhi, S et al. NEJM 2010

Incredible years for rotavirus vaccines!.... And great promise for the future!!

22 Acknowledgements